Clovis Oncology
CLVS
#9779
Rank
ยฃ9.35 M
Marketcap
ยฃ0.06453
Share price
0.00%
Change (1 day)
-95.07%
Change (1 year)

P/E ratio for Clovis Oncology (CLVS)

P/E ratio on February 22, 2023 (TTM): -0.0430

According to Clovis Oncology's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.042963. At the end of 2012 the company had a P/E ratio of -5.35.

P/E ratio history for Clovis Oncology from 2012 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2012-5.35

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
82.5-192,186.91%๐Ÿ‡บ๐Ÿ‡ธ USA
33.1-77,056.92%๐Ÿ‡ฌ๐Ÿ‡ง UK
13.8-32,198.08%๐Ÿ‡บ๐Ÿ‡ธ USA
11.0-25,741.60%๐Ÿ‡บ๐Ÿ‡ธ USA
48.1-112,000.24%๐Ÿ‡บ๐Ÿ‡ธ USA
138-320,778.26%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.